Related Experiment Video
Updated: Jul 15, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
TCAP gene is not a common cause of cardiomyopathy in Iranian patients
Zahra Alaei1,2, Nasrin Zamani2,3, Bahareh Rabbani3
1Faculty of Basic Sciences, Islamic Azad University, East Tehran Branch, Tehran, Iran.
Insights
Pathogenic mutations in the TCAP gene are not a common cause of hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) in Iranian patients. However, TCAP gene variants are linked to various conditions, including LGMD-2G, HCM, and DCM.
Area of Science:
- Cardiovascular Genetics
- Molecular Cardiology
- Genetic Medicine
Background:
- Hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) are leading causes of heart failure and sudden cardiac death.
- Genetic variants in Z-disc proteins, including telethonin (TCAP), are implicated in DCM and HCM etiology.
- TCAP gene mutations are associated with various neuromuscular and cardiac conditions.
Purpose of the Study:
- To investigate the role of the TCAP gene in Iranian patients diagnosed with cardiomyopathies.
- To identify novel pathogenic or likely pathogenic variants in the TCAP gene within this population.
- To review existing literature on TCAP gene variants and their associated phenotypes.
Main Methods:
- Genetic analysis of the TCAP gene in 40 unrelated Iranian patients with HCM or DCM.
- In-silico analysis to predict the pathogenicity of identified variants.
- Comprehensive literature and database review of reported TCAP gene variants.
Main Results:
- Only one intronic variant (c.111-42G>A) was found in an HCM patient, predicted as polymorphism.
- Literature review revealed 44 TCAP gene variants, predominantly missense mutations.
- TCAP mutations are linked to limb-girdle muscular dystrophy 2G (LGMD-2G), DCM, HCM, and other conditions, with LGMD-2G being the most frequent phenotype.
Conclusions:
- TCAP gene mutations appear uncommon as a cause of cardiomyopathy in the studied Iranian cohort.
- TCAP gene variants can manifest in diverse clinical presentations, notably LGMD-2G, HCM, and DCM.
- Further research may be needed to fully elucidate the TCAP gene's contribution to cardiomyopathies in diverse populations.
Background:
Hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) are the most frequent cardiomyopathies that cause acute heart failure and sudden cardiac death. Previous genetic reports have shown that pathogenic variants of genes encoding Z-disc components such as telethonin protein (TCAP) are the primary cause of DCM and HCM.
Methods:
This study was the first investigation on the TCAP gene among the Iranian cardiomyopathies population wherein the TCAP gene was analyzed in 40 unrelated patients (17 females and 23 males) who were clinically diagnosed with HCM and DCM. In addition, we conducted a thorough review of all published articles and the databases that were the first to report novel pathogenic or likely pathogenic variants the in TCAP gene.
Results:
In the cohort of this study, we identified only one intronic variant c.111-42G > A in one of the HCM patients that were predicted as polymorphism by in-silico analysis. Moreover, a total of 44 variants were reported for the TCAP gene in the literature where a majority of mutations were found to be missense. Pathogenic mutations in TCAP may cause diseases including limb-girdle muscular dystrophy 2G (LGMD-2G), DCM, HCM, intestinal pseudo-obstruction, and telethonin deficiency. However, a large number of affected patients were clinically diagnosed with limb-girdle 2G compared to other presenting phenotypes.
Discussion:
These findings suggest that the TCAP gene pathogenic mutations might not be a common cause of cardiomyopathies among Iranian patients. These gene disease-causing mutations may cause various manifestations, but it has a high prevalence among LGMD-2G, HCM, and DCM patients.
More Related Videos
Related Concept Videos
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

